Shu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shu Li has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Fen Li
Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Clinical Medical Research Center for Systemic Autoimmune Diseases in Hunan Province, Changsha, Hunan, P.R. China
3 shared publications- Fen Li
Department of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University
3 shared publications - Chujie Bai
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China
2 shared publications - Jiayong Liu
Department of Orthopedic Surgery, The University of Toledo Medical Center, Toledo, Ohio
2 shared publications Jinwei Chen
Department of Rheumatology and Immunology The Second Xiangya Hospital Central South University Changsha China
2 shared publications- Ruifeng Xue
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking Uni-versity Cancer Hospital & Institute, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 21 January 2026
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 27 (1)
Elucidating osteoporosis response signatures in rheumatoid arthritis using explainable machine learning ensembles
Background and objectives: Osteoporosis (OP) presents a significant health issue in rheumatoid arthritis (RA) patients, yet existing machine learning (ML) studies on OP prediction in this population are limited by low accuracy, a narrow range of considered risk factors, and a lack of interpretability. This study aims to develop an interpretable machine learning model using the CNN-SVM algorithm, integrated with interpretability techniques, for individualized osteoporosis risk assessment in RA patients. The model specifically focuses on the osteopenia stage, which has been overlooked in previous research, to better capture the different risk factors involved in the progression of osteoporosis in RA patients. Methods: We recruited 314 RA patients from the Department of Rheumatology and Immunology. Participants were categorized into osteoporosis, osteopenia, and normal groups based on lumbar spine or hip bone mineral density (BMD) T-scores. We constructed ML model to assess osteoporosis using a novel classification algorithm, CNN-SVM, and employed SHapley Additive exPlanations (SHAP) and Sankey diagram to investigate significant risk factors, rank risk factor contributions, and provide individualized feature contribution explanations. Results: A total of 16 candidate variables were included, and three classification models were constructed to predict osteoporosis versus osteopenia, osteoporosis versus normal, and osteopenia versus normal. The AUC values for the models were 0.83, 0.93, and 0.74, respectively. Feature importance analysis using SHAP identified several key predictors. Factors such as Vitamin D supplements, Synovitis in Both Knees, and gender were crucial for distinguishing normal from osteopenia. For differentiating osteoporosis, Alendronate Sodium, weight, and age consistently ranked as highly influential features across different comparisons. Feature importance analysis was performed, ranking risk factors and providing individualized explanations of feature contributions. Conclusions: The developed interpretable ML model shows promise for screening osteoporosis risk in patients with RA. Its ability to identify individual risk factors highlights its potential to facilitate personalized prevention and management strategies, pending further validation.
- 21 January 2026
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 27 (1)
Open AccessElucidating osteoporosis response signatures in rheumatoid arthritis using explainable machine learning ensembles
Background and objectives: Osteoporosis (OP) presents a significant health issue in rheumatoid arthritis (RA) patients, yet existing machine learning (ML) studies on OP prediction in this population are limited by low accuracy, a narrow range of considered risk factors, and a lack of interpretability. This study aims to develop an interpretable machine learning model using the CNN-SVM algorithm, integrated with interpretability techniques, for individualized osteoporosis risk assessment in RA patients. The model specifically focuses on the osteopenia stage, which has been overlooked in previous research, to better capture the different risk factors involved in the progression of osteoporosis in RA patients. Methods: We recruited 314 RA patients from the Department of Rheumatology and Immunology. Participants were categorized into osteoporosis, osteopenia, and normal groups based on lumbar spine or hip bone mineral density (BMD) T-scores. We constructed ML model to assess osteoporosis using a novel classification algorithm, CNN-SVM, and employed SHapley Additive exPlanations (SHAP) and Sankey diagram to investigate significant risk factors, rank risk factor contributions, and provide individualized feature contribution explanations. Results: A total of 16 candidate variables were included, and three classification models were constructed to predict osteoporosis versus osteopenia, osteoporosis versus normal, and osteopenia versus normal. The AUC values for the models were 0.83, 0.93, and 0.74, respectively. Feature importance analysis using SHAP identified several key predictors. Factors such as Vitamin D supplements, Synovitis in Both Knees, and gender were crucial for distinguishing normal from osteopenia. For differentiating osteoporosis, Alendronate Sodium, weight, and age consistently ranked as highly influential features across different comparisons. Feature importance analysis was performed, ranking risk factors and providing individualized explanations of feature contributions. Conclusions: The developed interpretable ML model shows promise for screening osteoporosis risk in patients with RA. Its ability to identify individual risk factors highlights its potential to facilitate personalized prevention and management strategies, pending further validation.
- 12 June 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 137, 112451
The efficacy and safety of JAK inhibitors in patients with adult-onset still's disease: A meta-analysis and systematic review
- 12 June 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 137, 112451
The efficacy and safety of JAK inhibitors in patients with adult-onset still's disease: A meta-analysis and systematic review
- Open Access
- 12 April 2023
- Published by Wiley in Thoracic Cancer
- Vol. 14 (13) , 1171-1178
Clinical features and risk factors of lung cancer in elderly patients with dermatomyositis
Background Although there are concerns about the association between dermatomyositis (DM) and malignancy, the clinical features in elderly DM patients with lung cancer are largely unknown. Here, we elucidated the clinical features and risk factors of lung cancer in elderly DM patients.Methods The data of elderly DM patients (>= 65 years old) with or without lung cancer admitted to the Second Xiangya Hospital, Central South University from January 2016 to November 2022 were retrospectively analyzed.Results Male patients with elderly onset DM (EODM) symptoms were found to be prone to lung cancer (p < 0.001). Elderly DM patients with lung cancer had a higher ratio of a history of smoking and were more likely to present with heliotrope rash, V sign and dysphasia and elevated monocyte-to-lymphocyte ratio (MLR) and there was a higher ratio of anti-TIF1-?-Ab-positive patients (all p < 0.05). Occurrence of interstitial lung disease (ILD), elevated aspartate aminotransferase (AST) and anti-aminoacyl-tRNA synthetase (anti-ARS)-antibody positive rates were less common in elderly DM patients with lung cancer than those without lung cancer (all p < 0.05). Multivariate logistic regression analysis showed smoking history (p = 0.011, OR = 4.532), elevated MLR (p = 0.018, OR = 1.159) and anti-TIF1-?-Ab-positive status (p = 0.034, OR = 8.529) were independently associated with the presence of lung cancer, while ILD might be a protective factor (p = 0.024, OR = 0.179) for lung cancer in elderly patients with DM.Conclusions Lung cancer is more common in male patients with EODM symptoms. Smoking, elevated MLR and being anti-TIF1-?-Ab-positive were associated with higher frequencies of lung cancer in elderly DM patients. It is necessary to screen lung cancer in elderly DM patients with a history of smoking, elevated MLR or being anti-TIF1-?-Ab-positive.
- 12 April 2023
- Published by Wiley in Thoracic Cancer
- Vol. 14 (13) , 1171-1178
Open AccessClinical features and risk factors of lung cancer in elderly patients with dermatomyositis
Background Although there are concerns about the association between dermatomyositis (DM) and malignancy, the clinical features in elderly DM patients with lung cancer are largely unknown. Here, we elucidated the clinical features and risk factors of lung cancer in elderly DM patients.Methods The data of elderly DM patients (>= 65 years old) with or without lung cancer admitted to the Second Xiangya Hospital, Central South University from January 2016 to November 2022 were retrospectively analyzed.Results Male patients with elderly onset DM (EODM) symptoms were found to be prone to lung cancer (p < 0.001). Elderly DM patients with lung cancer had a higher ratio of a history of smoking and were more likely to present with heliotrope rash, V sign and dysphasia and elevated monocyte-to-lymphocyte ratio (MLR) and there was a higher ratio of anti-TIF1-?-Ab-positive patients (all p < 0.05). Occurrence of interstitial lung disease (ILD), elevated aspartate aminotransferase (AST) and anti-aminoacyl-tRNA synthetase (anti-ARS)-antibody positive rates were less common in elderly DM patients with lung cancer than those without lung cancer (all p < 0.05). Multivariate logistic regression analysis showed smoking history (p = 0.011, OR = 4.532), elevated MLR (p = 0.018, OR = 1.159) and anti-TIF1-?-Ab-positive status (p = 0.034, OR = 8.529) were independently associated with the presence of lung cancer, while ILD might be a protective factor (p = 0.024, OR = 0.179) for lung cancer in elderly patients with DM.Conclusions Lung cancer is more common in male patients with EODM symptoms. Smoking, elevated MLR and being anti-TIF1-?-Ab-positive were associated with higher frequencies of lung cancer in elderly DM patients. It is necessary to screen lung cancer in elderly DM patients with a history of smoking, elevated MLR or being anti-TIF1-?-Ab-positive.
- Open Access
- 24 November 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1019911
Clinical features and therapeutic outcomes of alveolar soft part sarcoma in children: A single-center, retrospective study
Background: Alveolar soft part sarcoma (ASPS) is a rare sarcoma that has been shown to be highly effective to antiangiogenic agents and immune checkpoint inhibitors, but most reported studies about ASPS were concentrated on adult population. In this study, we aimed to describe the clinical features and therapeutic outcomes of ASPS in children.Methods: We retrospectively reviewed the records of patients with ASPS in our institution since Jan 2015. All patients included in this study were pathologically confirmed ASPS and aged under 12 years at the time of initial diagnosis. Demographic characteristics, tumor sizes, primary tumor sites, metastasis, treatments used, therapeutic responses and survivals were evaluated.Results: We identified a total of 56 patients to be initially diagnosed as ASPS since Jan 2015. A predisposition of high occurrence in head and neck (32.1%) was observed (versus 41.1% in limbs and 21.4% in trunk). 26 (46.4%) patients developed metastasis at the time of diagnosis or during follow-up. Tumors in tongue, pharynx and larynx had the least likelihood to metastasize (7.7%, P<0.05). Observation was recommended for 15 stage IV patients with only pulmonary metastasis. 7 (46.7%) patients remained stable until last follow up. The 1-year PFS rate was 83.3% and median progression-free survival time (PFS) was 29.4 months. 15 patients with progressive disease received mono or combined therapy. 11 patients received PD-1 monotherapy. 2 patients achieved partial response and 5 stable disease. The overall response rate was 18.2%. The median PFS of this group was 22.0 months, and the 1-year PFS rate was 70.0%. 4 patients received a combination therapy of PD-1 inhibitors plus tyrosine kinase inhibitors. All of them remained stable. No disease-related death occurred during follow-up.Conclusions: ASPS exhibits a higher occurrence in head and neck in children. ASPS originating from glossopharyngeal region tends to have a lower metastasis rate. ASPS displays a more indolent growth pattern in children, which makes observation a preferable choice for children with sole pulmonary metastasis. Pediatric ASPS appears to be less effective to targeted therapy and immunotherapy than adults. The treatment of progressive ASPS in children remains challenging.
- 24 November 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1019911
Open AccessClinical features and therapeutic outcomes of alveolar soft part sarcoma in children: A single-center, retrospective study
Background: Alveolar soft part sarcoma (ASPS) is a rare sarcoma that has been shown to be highly effective to antiangiogenic agents and immune checkpoint inhibitors, but most reported studies about ASPS were concentrated on adult population. In this study, we aimed to describe the clinical features and therapeutic outcomes of ASPS in children.Methods: We retrospectively reviewed the records of patients with ASPS in our institution since Jan 2015. All patients included in this study were pathologically confirmed ASPS and aged under 12 years at the time of initial diagnosis. Demographic characteristics, tumor sizes, primary tumor sites, metastasis, treatments used, therapeutic responses and survivals were evaluated.Results: We identified a total of 56 patients to be initially diagnosed as ASPS since Jan 2015. A predisposition of high occurrence in head and neck (32.1%) was observed (versus 41.1% in limbs and 21.4% in trunk). 26 (46.4%) patients developed metastasis at the time of diagnosis or during follow-up. Tumors in tongue, pharynx and larynx had the least likelihood to metastasize (7.7%, P<0.05). Observation was recommended for 15 stage IV patients with only pulmonary metastasis. 7 (46.7%) patients remained stable until last follow up. The 1-year PFS rate was 83.3% and median progression-free survival time (PFS) was 29.4 months. 15 patients with progressive disease received mono or combined therapy. 11 patients received PD-1 monotherapy. 2 patients achieved partial response and 5 stable disease. The overall response rate was 18.2%. The median PFS of this group was 22.0 months, and the 1-year PFS rate was 70.0%. 4 patients received a combination therapy of PD-1 inhibitors plus tyrosine kinase inhibitors. All of them remained stable. No disease-related death occurred during follow-up.Conclusions: ASPS exhibits a higher occurrence in head and neck in children. ASPS originating from glossopharyngeal region tends to have a lower metastasis rate. ASPS displays a more indolent growth pattern in children, which makes observation a preferable choice for children with sole pulmonary metastasis. Pediatric ASPS appears to be less effective to targeted therapy and immunotherapy than adults. The treatment of progressive ASPS in children remains challenging.
- 27 April 2022
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 52 (8) , e13791
Iguratimod inhibits skin fibrosis by regulating TGF‐β1/Smad signalling pathway in systemic sclerosis
Background: Iguratimod (T‐614), exerting a powerful anti‐inflammatory ability, has therapeutic efficacy in multiple autoimmune diseases. However, the effect of T‐614 on systemic sclerosis (SSc) is unclear. Here, we investigate the effect and molecular mechanism of T‐614 in experimental SSc models.Methods: In vitro, cultured dermal fibroblasts from four SSc patients were subjected to different doses of T‐614 in the presence or absence of TGF‐β1 stimulation. Cell proliferation, apoptosis and migration were determined by CCK‐8, flow cytometry and transwell assay, respectively. Fibrosis markers and smad signalling pathway‐related proteins were detected by immunoblotting and immunofluorescence. In vivo, a bleomycin‐induced SSc mouse model was used to evaluate the effect of T‐614 on skin fibrosis. Pathological changes in skin tissues were evaluated by HE, Masson staining and immunohistochemistry.Results: In the study, we found T‐614 inhibited TGF‐β1‐induced cell proliferation, migration and promoted apoptosis in a dose‐dependent manner (all p < 0.01). T‐614 partially reversed TGF‐β1‐induced upregulation of fibrosis markers and phosphorylation of smad2 and smad3 and blocked p‐Smad3 nuclear translocation (all p < 0.05), suggesting T‐614 may inhibit dermal fibroblasts activation by regulating TGF‐β1/smad pathway. In vivo experiments, T‐614 alleviated skin thickness in bleomycin‐induced SSc mice (all p < 0.05). The expression of fibrosis markers and the infiltration of macrophages in skin tissue were significantly decreased after T‐614 treatment (all p < 0.05).Conclusion: Our preliminary data indicated T‐614 inhibited dermal fibroblasts activation and skin fibrosis at least partly by regulating TGF‐β1/smad pathway in experimental SSc models and may be a promising therapeutic agent for SSc.
- 27 April 2022
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 52 (8) , e13791
Iguratimod inhibits skin fibrosis by regulating TGF‐β1/Smad signalling pathway in systemic sclerosis
Background: Iguratimod (T‐614), exerting a powerful anti‐inflammatory ability, has therapeutic efficacy in multiple autoimmune diseases. However, the effect of T‐614 on systemic sclerosis (SSc) is unclear. Here, we investigate the effect and molecular mechanism of T‐614 in experimental SSc models.Methods: In vitro, cultured dermal fibroblasts from four SSc patients were subjected to different doses of T‐614 in the presence or absence of TGF‐β1 stimulation. Cell proliferation, apoptosis and migration were determined by CCK‐8, flow cytometry and transwell assay, respectively. Fibrosis markers and smad signalling pathway‐related proteins were detected by immunoblotting and immunofluorescence. In vivo, a bleomycin‐induced SSc mouse model was used to evaluate the effect of T‐614 on skin fibrosis. Pathological changes in skin tissues were evaluated by HE, Masson staining and immunohistochemistry.Results: In the study, we found T‐614 inhibited TGF‐β1‐induced cell proliferation, migration and promoted apoptosis in a dose‐dependent manner (all p < 0.01). T‐614 partially reversed TGF‐β1‐induced upregulation of fibrosis markers and phosphorylation of smad2 and smad3 and blocked p‐Smad3 nuclear translocation (all p < 0.05), suggesting T‐614 may inhibit dermal fibroblasts activation by regulating TGF‐β1/smad pathway. In vivo experiments, T‐614 alleviated skin thickness in bleomycin‐induced SSc mice (all p < 0.05). The expression of fibrosis markers and the infiltration of macrophages in skin tissue were significantly decreased after T‐614 treatment (all p < 0.05).Conclusion: Our preliminary data indicated T‐614 inhibited dermal fibroblasts activation and skin fibrosis at least partly by regulating TGF‐β1/smad pathway in experimental SSc models and may be a promising therapeutic agent for SSc.
- Open Access
- 18 February 2021
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (1) , 280-288
Resveratrol promotes apoptosis and G2/M cell cycle arrest of fibroblast-like synoviocytes in rheumatoid arthritis through regulation of autophagy and the serine-threonine kinase-p53 axis
Introduction: Resveratrol, a polyphenol extracted from many plant species, has emerged as a promising pro-apoptotic agent in various cancer cells. However, the role of resveratrol in cell proliferation and apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis (RA-FLS) is not fully understood. The study was aimed at elucidating the role of resveratrol in cell proliferation and apoptosis of RA-FLS and the underlying molecular mechanism.Material and methods: Cultured RA-FLSs were subjected to tumour necrosis factor (TNF-). The cell proliferation was measured by Cell Counting Kit-8 assay. Cell apoptosis and cell cycle of RA-FLSs were determined by flow cytometry. The levels of apoptosis or autophagy or cell cycle-related protein were detected by immunoblot analysis.Results: In our study, we confirmed that resveratrol reversed TNF- mediated cell proliferation in RA-FLS. Meanwhile, resveratrol blocked cells at the G2/M stage and reduced the ratio of S phase cells through upregulation of p53 and consequently led to apoptotic cell death. Quite interestingly, we found that resveratrol reversed TNF--induced autophagy. Inhibition of autophagy by resveratrol or autophagy inhibitor or Beclin-1 siRNA suppressed TNF- mediated cell survival and promoted cell apoptosis. However, the autophagy inducer rapamycin (RAPA) reversed the effect of resveratrol on autophagy and cell proliferation. Mechanistic studies revealed that resveratrol inhibited the activation of the phosphoinositide 3-kinases/serine-threonine kinase (PI3K/AKT) pathway. Inhibition of PI3K/AKT pathway by inhibitor LY294002 or resveratrol increased the expression of p53 and decreased the expression of cycle protein (cyclin B1), which further led to block cells in the G2/M arrest.Conclusions: Our preliminary study indicated that resveratrol may suppress RA-FLS cell survival and promote apoptosis at least partly through regulation of autophagy and the AKT-p53 axis.
- 18 February 2021
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (1) , 280-288
Open AccessResveratrol promotes apoptosis and G2/M cell cycle arrest of fibroblast-like synoviocytes in rheumatoid arthritis through regulation of autophagy and the serine-threonine kinase-p53 axis
Introduction: Resveratrol, a polyphenol extracted from many plant species, has emerged as a promising pro-apoptotic agent in various cancer cells. However, the role of resveratrol in cell proliferation and apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis (RA-FLS) is not fully understood. The study was aimed at elucidating the role of resveratrol in cell proliferation and apoptosis of RA-FLS and the underlying molecular mechanism.Material and methods: Cultured RA-FLSs were subjected to tumour necrosis factor (TNF-). The cell proliferation was measured by Cell Counting Kit-8 assay. Cell apoptosis and cell cycle of RA-FLSs were determined by flow cytometry. The levels of apoptosis or autophagy or cell cycle-related protein were detected by immunoblot analysis.Results: In our study, we confirmed that resveratrol reversed TNF- mediated cell proliferation in RA-FLS. Meanwhile, resveratrol blocked cells at the G2/M stage and reduced the ratio of S phase cells through upregulation of p53 and consequently led to apoptotic cell death. Quite interestingly, we found that resveratrol reversed TNF--induced autophagy. Inhibition of autophagy by resveratrol or autophagy inhibitor or Beclin-1 siRNA suppressed TNF- mediated cell survival and promoted cell apoptosis. However, the autophagy inducer rapamycin (RAPA) reversed the effect of resveratrol on autophagy and cell proliferation. Mechanistic studies revealed that resveratrol inhibited the activation of the phosphoinositide 3-kinases/serine-threonine kinase (PI3K/AKT) pathway. Inhibition of PI3K/AKT pathway by inhibitor LY294002 or resveratrol increased the expression of p53 and decreased the expression of cycle protein (cyclin B1), which further led to block cells in the G2/M arrest.Conclusions: Our preliminary study indicated that resveratrol may suppress RA-FLS cell survival and promote apoptosis at least partly through regulation of autophagy and the AKT-p53 axis.
- Open Access
- 16 June 2020
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11, 620
An Analysis Regarding the Association Between the ISLR Gene and Gastric Carcinogenesis
For datasets of gastric cancer collected by TCGA (The Cancer Genome Atlas) and GEO (Gene Expression Omnibus) repositories, we applied a bioinformatics approach to obtain expression data for the ISLR (immunoglobulin superfamily containing leucine-rich repeat) gene, which is highly expressed in gastric cancer tissues and closely associated with clinical prognosis. Although we did not observe an overall association of ISLR mutation, high expression or copy number variation with survival, hypomethylation of four methylated sites (assessed by the probes cg05195566, cg17258195, cg09664357, and cg07297039) of ISLR was negatively correlated with high expression levels of ISLR and was associated with poor clinical prognosis. In addition, we detected a correlation between ISLR expression and the infiltration levels of several immune cells, especially CD8+ T cells, macrophages and dendritic cells. We also identified a series of genes that were positively and negatively correlated with ISLR expression based on the TCGA-STAD, GSE13861, and GSE29272 datasets. Principal component analysis and random forest analysis were employed to further screen for six hub genes, including ISLR, COL1A2, CDH11, SPARC, COL3A1, and COL1A1, which exhibited a good ability to differentiate between tumor and normal samples. GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway and gene set enrichment analysis data also suggested a potential relationship between ISLR gene expression and epithelial-mesenchymal transition (EMT). ISLR expression was negatively correlated with sensitivity to PX-12 and NSC632839. Taken together, these results show that the ISLR gene is involved in gastric carcinogenesis, and the underlying molecular mechanisms may include DNA methylation, EMT, and immune cell infiltration.
- 16 June 2020
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11, 620
Open AccessAn Analysis Regarding the Association Between the ISLR Gene and Gastric Carcinogenesis
For datasets of gastric cancer collected by TCGA (The Cancer Genome Atlas) and GEO (Gene Expression Omnibus) repositories, we applied a bioinformatics approach to obtain expression data for the ISLR (immunoglobulin superfamily containing leucine-rich repeat) gene, which is highly expressed in gastric cancer tissues and closely associated with clinical prognosis. Although we did not observe an overall association of ISLR mutation, high expression or copy number variation with survival, hypomethylation of four methylated sites (assessed by the probes cg05195566, cg17258195, cg09664357, and cg07297039) of ISLR was negatively correlated with high expression levels of ISLR and was associated with poor clinical prognosis. In addition, we detected a correlation between ISLR expression and the infiltration levels of several immune cells, especially CD8+ T cells, macrophages and dendritic cells. We also identified a series of genes that were positively and negatively correlated with ISLR expression based on the TCGA-STAD, GSE13861, and GSE29272 datasets. Principal component analysis and random forest analysis were employed to further screen for six hub genes, including ISLR, COL1A2, CDH11, SPARC, COL3A1, and COL1A1, which exhibited a good ability to differentiate between tumor and normal samples. GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway and gene set enrichment analysis data also suggested a potential relationship between ISLR gene expression and epithelial-mesenchymal transition (EMT). ISLR expression was negatively correlated with sensitivity to PX-12 and NSC632839. Taken together, these results show that the ISLR gene is involved in gastric carcinogenesis, and the underlying molecular mechanisms may include DNA methylation, EMT, and immune cell infiltration.
- 20 January 2013
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 33 (1) , 100-103
A comparison between preoperative PET/CT and CT images of long bone osteosarcoma of the lower extremity
- 20 January 2013
- Published by China Science Publishing & Media Ltd. in Academic Journal of Second Military Medical University
- Vol. 33 (1) , 100-103
A comparison between preoperative PET/CT and CT images of long bone osteosarcoma of the lower extremity